Ameregen is an investment portfolio of post-launch and late stage bio-engineering, nano-tech, and stem cell therapies.
Current main focus of my daily work is in international high-finance/structured finance/VC/SPV/Hedge Funds & banks. The Ameregen Group has exclusive access to assets that are valued at $29 billion (international accounting) in cancer specialty therapeutics manufacturing, sales, marketing and distribution rights for key (non-US minded) nations, in SPVs. Monetizing these assets with exclusive launch partners in state-of-the-art advanced cancer care hospitals is current.
Ameregen is a Venture Philanthropy Corporation. The group just announced a $250,000,000.00 matching grant to go to either USC's Larry Ellison Institute of Transformational Medicine or to Stanford LPCH adding a state-of-the-art advanced cancer-rescue division where patients can self-select not to receive chemotherapies and seek cures via cell therapies.
Successful serial entrepreneur in the emergent stem cell pharmaceuticals industry. Specialties: launch team building, ultra-high-performance life science, personalized medicine, adv. cancer-rescues, intl. high-finance/structured finance, automated cGMP manufacturing of cellular therapeutics with economies of scale, high-tech/high-growth management, disruptive cancer therapeutics: R&D, immune proteomics, cellular cancer immunity, bench-to-bedside, clinic systems.
Supporting Media/TV/Health/Cancer-Help Channels, Public Speaker, Public Awareness - Domain Expert on Stem Cells.
What I love about Ameregen are the people and the cutting edge, state of the art adult stem cell industry. I strongly believe in our field. Occasionally, I make myself available as Board Member to help other stem cell companies thrive.
I lead by excellence, encouragement, and example solving challenges by win-win state-of-the-art solutions that are typically "out-of-the-box", team and patient centered, and cross-disciplinary approaches. Important to me to stay true to who I am and what I believe - please note that I believe in treating cancer without chemotherapies as there is no data that shows survival benefits since introduction of the cruel and expensive chemotherapies in the 1950s. I have seen our fully approved CITA cell therapies acutely destroy advanced stage IV, multi-drug-resistant cancers in as little as 4 hours and patients who were declared as good as dead 10 years ago are now my long-term surviving dear friends, cured. My mission in life is the 2018 roll-out of the Eradicate Cancer 2018 Project, partnering with pioneering philanthropists. Ameregen contributes the much needed CITA cancer rescue technology that is faster, cheaper, better, side-effect free.